Scholarlink

On February 10, 2022, AstraZeneca (“AZ”), a global pharmaceutical giant, announced its FY2021 results. Total revenue for 2021 was up 41% to US$ 37.41 billion, of which AstraZeneca China (“AZ-China”) contributed some US$ 6 billion as it continued to outperform other pharmaceutical multinationals in China.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AstraZeneca (China): Promoting Social Innovation with Holistic Disease Management Solutions Throughout the Patient Journey

  • 章节

  • 发表日期：

    2025年

查看全文
  • Wang Hong,
  • Dominique Turpin

摘要

On February 10, 2022, AstraZeneca (“AZ”), a global pharmaceutical giant, announced its FY2021 results. Total revenue for 2021 was up 41% to US$ 37.41 billion, of which AstraZeneca China (“AZ-China”) contributed some US$ 6 billion as it continued to outperform other pharmaceutical multinationals in China.